Dana Dunn, MS

Regulatory Advisor

Dana brings more than 25 years of experience in regulatory strategy and drug development, specializing in oncology and rare disease programs. She has guided numerous biopharmaceutical companies through successful FDA submissions, including pre-IND, IND, and Breakthrough Therapy Designation processes, helping advance innovative treatments from concept to clinic.

As Regulatory Advisor to Lumigen, Dana leads the company’s regulatory planning and FDA engagement strategy, ensuring a clear and compliant path to first-in-human studies. Her expertise supports efficient development of Lumigen’s targeted cancer therapies while reducing regulatory risk.

Dana holds an MS in Regulatory Affairs from Johns Hopkins University and a BS in Biology from the University of Maryland.